Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:IRDNASDAQ:MOLNNASDAQ:OGI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$2.83-2.4%$3.21$2.30▼$5.54$169.47M0.08276,436 shs240,734 shsIRDOpus Genetics$0.95-1.0%$0.91$0.65▼$1.56$43.21M0.06215,330 shs148,580 shsMOLNMolecular Partners$3.91-1.8%$3.99$3.36▼$12.70$157.87M1.1520,858 shs2,122 shsOGIOrganigram$1.22-1.6%$1.06$0.85▼$2.11$163.28M1.35683,447 shs425,126 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals-2.41%-5.73%-5.03%-36.97%+20.94%IRDOpus Genetics-0.96%-6.86%+15.49%-17.39%+94,999,900.00%MOLNMolecular Partners-1.76%-4.73%+1.30%-24.30%+10.14%OGIOrganigram-1.61%+9.42%+17.31%-9.63%-33.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.1697 of 5 stars3.52.00.00.03.51.70.0IRDOpus Genetics2.0139 of 5 stars3.50.00.00.02.40.01.3MOLNMolecular Partners2.203 of 5 stars3.82.00.00.03.30.00.6OGIOrganigram0.1362 of 5 stars0.01.00.00.00.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$12.50341.70% UpsideIRDOpus Genetics 3.00Buy$7.33671.93% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00206.91% UpsideOGIOrganigram 3.00BuyN/AN/ACurrent Analyst Ratings BreakdownLatest IRD, MOLN, ELDN, and OGI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025IRDOpus GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.004/1/2025IRDOpus GeneticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.004/1/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/19/2025IRDOpus GeneticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AIRDOpus Genetics$10.99M3.93N/AN/A$2.20 per share0.43MOLNMolecular Partners$4.97M31.76N/AN/A$5.41 per share0.72OGIOrganigram$166.12M0.98N/AN/A$1.83 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$116.54M-$2.36N/AN/AN/AN/A-189.99%-28.17%5/15/2025 (Estimated)IRDOpus Genetics-$9.99M-$2.15N/AN/AN/A-324.45%-63.65%-56.94%5/16/2025 (Estimated)MOLNMolecular Partners-$69.04M-$1.81N/AN/AN/A-1,043.01%-39.31%-35.46%5/15/2025 (Estimated)OGIOrganigram-$33.39M$0.10N/AN/AN/A-31.69%-8.59%-6.54%N/ALatest IRD, MOLN, ELDN, and OGI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025N/AIRDOpus Genetics-$0.34-$1.27-$0.93N/A$4.00 million$4.30 million5/14/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28-$0.08+$0.20-$0.08N/AN/A3/31/2025Q4 2024IRDOpus Genetics-$0.34-$1.27-$0.93-$1.27$11.10 million$3.40 million3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/A3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AOGIOrganigramN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A6.536.53IRDOpus GeneticsN/A6.636.63MOLNMolecular PartnersN/A14.3314.33OGIOrganigramN/A3.361.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%IRDOpus Genetics14.97%MOLNMolecular Partners26.55%OGIOrganigram34.63%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals11.70%IRDOpus Genetics6.60%MOLNMolecular Partners5.93%OGIOrganigram0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableIRDOpus Genetics1445.48 million29.49 millionN/AMOLNMolecular Partners18040.38 million37.97 millionNot OptionableOGIOrganigram860133.84 million126.10 millionOptionableIRD, MOLN, ELDN, and OGI HeadlinesRecent News About These CompaniesOrganigram (NASDAQ:OGI) Releases Earnings Results, Misses Expectations By $0.10 EPSMay 14 at 7:54 AM | marketbeat.comEarnings call transcript: OrganiGram’s Q2 2025 revenue surges 74%May 14 at 4:54 AM | uk.investing.comOrganiGram (OGI) Reports Q2 Loss, Beats Revenue Estimates (Revised)May 12 at 8:15 PM | zacks.comOrganiGram (OGI) Reports Q2 Loss, Misses Revenue EstimatesMay 12 at 8:45 AM | zacks.comOrganigram (OGI) Expected to Announce Quarterly Earnings on MondayMay 10, 2025 | americanbankingnews.comInsights Ahead: OrganiGram Holdings's Quarterly EarningsMay 9, 2025 | benzinga.comOrganigram (OGI) to Release Earnings on MondayMay 7, 2025 | marketbeat.comOrganigram Global Wins "Exporter of the Year" at the 2025 New Brunswick Export AwardsMay 5, 2025 | finance.yahoo.comOrganigram Global Wins “Exporter of the Year” at the 2025 New Brunswick Export AwardsMay 5, 2025 | businesswire.comOrganigram to Report Second Quarter Fiscal 2025 Results on May 12, 2025May 2, 2025 | businesswire.comOrganigram Global’s Products Recognized at the CNB AwardsApril 24, 2025 | finance.yahoo.comOrganigram Global's Products Recognized at the CNB AwardsApril 24, 2025 | businesswire.comOrganigram Global Shares Recording of its OG Investor SessionApril 22, 2025 | businesswire.comOrganigram Global Announces Acquisition Of Collective Project Limited - Quick FactsApril 3, 2025 | nasdaq.comOrganigram Global Inc. (OGI.TO)April 2, 2025 | ca.finance.yahoo.comOrganigram Global to Host the OG Investor Session, its Inaugural Virtual Event for Investors, and Announcement of Name Change on TSX and NASDAQApril 2, 2025 | businesswire.comOrganigram acquires Collective Project for C$6.2MApril 2, 2025 | markets.businessinsider.comTop 5 cannabis stocks with operations in CanadaApril 1, 2025 | msn.comStocks in play: Organigram Global Inc.April 1, 2025 | ca.finance.yahoo.comOrganigram Enters U.S. Through Acquisition of Collective Project BeveragesApril 1, 2025 | businesswire.comOrganigram Rebrands to Reflect Global Expansion AmbitionsMarch 26, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongAST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockBy Jea Yu | April 21, 2025View AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer StockIRD, MOLN, ELDN, and OGI Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$2.83 -0.07 (-2.41%) As of 05/14/2025 04:00 PM EasternEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Opus Genetics NASDAQ:IRD$0.95 -0.01 (-0.96%) As of 05/14/2025 04:00 PM EasternOpus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Molecular Partners NASDAQ:MOLN$3.91 -0.07 (-1.76%) As of 05/14/2025 01:32 PM EasternMolecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Organigram NASDAQ:OGI$1.22 -0.02 (-1.61%) As of 05/14/2025 04:00 PM EasternOrganigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
